TY - JOUR

T1 - Quantification of [(123)I]PE2I binding to dopamine transporters with SPET

AU - Pinborg, Lars H

AU - Videbaek, Charlotte

AU - Svarer, Claus

AU - Yndgaard, Stig

AU - Paulson, Olaf B

AU - Knudsen, Gitte M

PY - 2002/5

Y1 - 2002/5

N2 - The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with single-photon emission tomography (SPET). The aim of the present study was to describe a method for accurate quantification of binding data following a bolus injection of [(123)I]PE2I. Six healthy subjects (age 51+/-24 years) underwent xenon-133 SPET for quantification of regional CBF and [(123)I]PE2I SPET for quantification of DAT binding. rCBFs were within normal limits in all subjects. Fitting data to a two-tissue compartment model resulted in striatal K(1) values of 0.39+/-0.08 ml ml(-1) min(-1), equal to a first-pass extraction fraction of 0.72+/-0.13. Distribution volumes (DVs) were calculated using compartment analysis, area under the curve analysis and Logan analysis. Logan analysis is preferred since stable DV values were already obtained 120 min after [(123)I]PE2I injection. Mean striatal DV was 37.9+/-9.6 ml ml(-1) and mean occipital cortex DV was 5.5+/-0.7 ml ml(-1). In the absence of local pathology in a reference tissue, Logan analysis without blood sampling is an attractive method for accurate quantification of striatal [(123)I]PE2I binding. The distribution volume ratio (DVR) (6.6+/-1.4) was in good agreement with the DVR calculated with blood (6.7+/-1.4).

AB - The iodinated cocaine derivative [(123)I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with single-photon emission tomography (SPET). The aim of the present study was to describe a method for accurate quantification of binding data following a bolus injection of [(123)I]PE2I. Six healthy subjects (age 51+/-24 years) underwent xenon-133 SPET for quantification of regional CBF and [(123)I]PE2I SPET for quantification of DAT binding. rCBFs were within normal limits in all subjects. Fitting data to a two-tissue compartment model resulted in striatal K(1) values of 0.39+/-0.08 ml ml(-1) min(-1), equal to a first-pass extraction fraction of 0.72+/-0.13. Distribution volumes (DVs) were calculated using compartment analysis, area under the curve analysis and Logan analysis. Logan analysis is preferred since stable DV values were already obtained 120 min after [(123)I]PE2I injection. Mean striatal DV was 37.9+/-9.6 ml ml(-1) and mean occipital cortex DV was 5.5+/-0.7 ml ml(-1). In the absence of local pathology in a reference tissue, Logan analysis without blood sampling is an attractive method for accurate quantification of striatal [(123)I]PE2I binding. The distribution volume ratio (DVR) (6.6+/-1.4) was in good agreement with the DVR calculated with blood (6.7+/-1.4).

KW - Area Under Curve

KW - Cerebral Cortex/blood supply

KW - Cerebrovascular Circulation

KW - Corpus Striatum/blood supply

KW - Dopamine Plasma Membrane Transport Proteins

KW - Humans

KW - Membrane Glycoproteins

KW - Membrane Transport Proteins/metabolism

KW - Middle Aged

KW - Models, Biological

KW - Models, Chemical

KW - Nerve Tissue Proteins

KW - Nortropanes/pharmacokinetics

KW - Phantoms, Imaging

KW - Radiopharmaceuticals/pharmacokinetics

KW - Sensitivity and Specificity

KW - Tissue Distribution

KW - Tomography, Emission-Computed, Single-Photon

KW - Xenon Radioisotopes/pharmacokinetics

U2 - 10.1007/s00259-001-0742-9

DO - 10.1007/s00259-001-0742-9

M3 - Journal article

C2 - 11976800

VL - 29

SP - 623

EP - 631

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 5

ER -